- ►annals.org HLY Chan, EJ Heathcote, P Marcellin, CL Lai, … - Annals of Internal Medicine, 2007 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Background: The efficacy of nucleoside and nucleotide analogues for ... Cited by 74 - Related articles - BL Direct - All 9 versions
CL Lai, E Gane, YF Liaw, CW Hsu, S … - The New England Journal of Medicine, 2007 - nejm.highwire.org From the University Department of Med- icine, Queen Mary Hospital, Hong Kong
(C.-LL); Middlemore Hospital, Auckland, New Zealand (EG); Chang Gung Memo- rial
Hospital, Chang Gung University Col- lege of Medicine, Taipei, Taiwan ... Cited by 175 - Related articles - BL Direct - All 6 versions
- ►radiologysource.org JJY Sung, JY Lai, S Zeuzem, WC Chow, EJ … - Journal of Hepatology, 2008 - Elsevier Time-weighted average change in serum HBV DNA from baseline up to week 16 was
−4.20 log 10 copies/mL for both groups (p = 0.936). At week 104, median serum
HBV DNA change from baseline (log 10 copies/mL) for monotherapy and ... Cited by 52 - Related articles - All 18 versions
- ►sebivo.com.ua [PDF] CL Lai, N Leung, EK Teo, M Tong, F Wong, … - Gastroenterology, 2005 - Elsevier Background & Aims: A previous 4-week trial of telbivudine in patients with
chronic hepatitis B indicated marked antiviral effects with good tolerability,
leading to the present 1-year phase 2b trial. Methods: This randomized, ... Cited by 269 - Related articles - All 5 versions
- ►nih.gov XJ Zhou, BA Fielman, DM Lloyd, GC Chao, … - Antimicrobial agents and chemotherapy, 2006 - aac.highwire.org Two phase I studies were conducted to assess the plasma pharmacokinetics of
telbivudine and potential drug-drug interactions between telbivudine (200 or 600
mg/day) and lamivudine (100 mg/day) or adefovir dipivoxil (10 mg/day) in ... Cited by 28 - Related articles - BL Direct - All 9 versions
- ►ucsf.edu [PDF] EB Keeffe, S Zeuzem, RS Koff, DT Dieterich, R … - Clinical Gastroenterology and Hepatology, 2007 - Elsevier An international group of experienced hepatologists and virologists conducted a
single-day workshop to review the management of patients with chronic hepatitis
B receiving treatment with oral nucleosides or nucleotides. Guidelines ... Cited by 121 - Related articles - All 13 versions
[CITATION] weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy …
- ►journalacs.org YF Liaw, E Gane, N Leung, S Zeuzem, Y Wang … - Gastroenterology, 2009 - Elsevier The therapeutic response to telbivudine was superior to that of lamivudine in
HBeAg-positive (63% vs 48%; P < .001) and HBeAg-negative (78% vs 66%; P = .007)
patients. HBeAg-positive patients given telbivudine also had better ... Cited by 42 - Related articles - All 8 versions
J Hou, YK Yin, D Xu, D Tan, J Niu, X Zhou, Y … - Hepatology, 2008 - interscience.wiley.com Chronic hepatitis B and its life-threatening sequelae are highly prevalent in
China. There is a need for effective new therapies to suppress hepatitis B virus
(HBV) replication and ameliorate liver disease. In this study, we compared ... Cited by 41 - Related articles - BL Direct - All 4 versions
CL Lai, SG Lim, NA Brown, XJ Zhou, DM … - Hepatology, 2004 - interscience.wiley.com Current therapy for chronic hepatitis B is suboptimal as a result of limited
durable response rates, cumulative viral resistance, and/or poor tolerability.
Telbivudine has potent antiviral activity against hepatitis B virus (HBV) ... Cited by 99 - Related articles - All 3 versions
